Surmodics | SRDX - Current Liabilities


Surmodics reported $19.44M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Align Technology USD 1.91B 14.16M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Artivion USD 92.7M 8.86M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Boston Scientific USD 4.57B 868M Mar/2026
EDAP TMS EUR 31.4M 2.71M Sep/2025
Edwards Lifesciences USD 1.41B 404.7M Mar/2026
Haemonetics USD 282.6M 257.27M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Merit Medical Systems USD 216.87M 22.89M Mar/2026
Mesa Laboratories USD 54.4M 6.1M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Option Care Health USD 729.74M 99.6M Mar/2026
Stryker USD 6.32B 1.48B Mar/2026
Surmodics USD 19.44M 1.1M Jun/2025
Trinity Biotech USD 34.49M 2.97M Sep/2025